A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

Status:
Recruiting

Trial end date:
2025-04-30

Target enrollment:

Participant gender:

A study in healthy male and female participants of non-childbearing potential who have overweight or obesity

Phase 1

AstraZeneca

Parexel